Reminder: trastuzumab biosimilar strategy

CarePartners of Connecticut is offering a reminder pertaining to our biosimilar strategy for medical oncology drugs — specifically those in the trastuzumab drug class.

The preferred trastuzumab biosimilars are Kanjinti and Trazimera. As a reminder, prior authorization is required for all non-preferred trastuzumab products, which include Herceptin, Herceptin Hylecta, Ogivri, Herzuma, and Ontruzant.

For complete details, please refer to our Medicare Part B Step Therapy Medical Necessity Guidelines.